Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roivant Sciences ( (ROIV) ) just unveiled an announcement.
On March 16, 2025, Roivant Sciences, Inc. entered into a consulting agreement with its former Chief Accounting Officer, Rakhi Kumar, who stepped down on February 20, 2025. This agreement allows Ms. Kumar to provide advisory and transition services while continuing to vest into her equity incentive awards over an 18-month term, potentially impacting her and the company’s operational continuity.
More about Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on developing innovative therapies and technologies to address unmet medical needs.
YTD Price Performance: -9.44%
Average Trading Volume: 4,696,718
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.64B
See more data about ROIV stock on TipRanks’ Stock Analysis page.